BV02
CAS No. 292870-53-2
BV02 ( 2-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)-1,3-dioxoisoindoline-5-carboxylic acid )
产品货号. M28532 CAS No. 292870-53-2
BV02 is an inhibitor of 14-3-3 protein-protein interactions and can be used in studies about the treatment of chronic myeloid leukemia. BV02 disrupts hematopoietic cells expressing the IM-resistant T315I mutation and the IM-sensitive wild-type Bcr-Abl.
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
规格 | 价格/人民币 | 库存 | 数量 |
2MG | ¥421 | 有现货 |
|
5MG | ¥680 | 有现货 |
|
10MG | ¥1037 | 有现货 |
|
25MG | ¥2341 | 有现货 |
|
50MG | ¥3686 | 有现货 |
|
100MG | ¥5443 | 有现货 |
|
500MG | ¥11583 | 有现货 |
|
1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称BV02
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述BV02 is an inhibitor of 14-3-3 protein-protein interactions and can be used in studies about the treatment of chronic myeloid leukemia. BV02 disrupts hematopoietic cells expressing the IM-resistant T315I mutation and the IM-sensitive wild-type Bcr-Abl.
-
产品描述BV02 is an inhibitor of 14-3-3 protein-protein interactions and can be used in studies about the treatment of chronic myeloid leukemia. BV02 disrupts hematopoietic cells expressing the IM-resistant T315I mutation and the IM-sensitive wild-type Bcr-Abl.
-
同义词2-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)-1,3-dioxoisoindoline-5-carboxylic acid
-
通路Others
-
靶点Other Targets
-
受体——
-
研究领域——
-
适应症——
化学信息
-
CAS Number292870-53-2
-
分子量377.4
-
分子式C20H15N3O5
-
纯度>98% (HPLC)
-
溶解度——
-
SMILESO=C(O)C1=CC=C2C(=O)N(C(=O)C2=C1)C=3C(=O)N(C=4C=CC=CC4)N(C3C)C
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
产品手册
关联产品
-
DL -34-Dihydroxymand...
34-Dihydroxymandelic acid is a minor metabolite of norepinephrine in humans.
-
Methyl nomilinate
Methyl nomilinate from citrus can modulate cell cycle regulators to induce cytotoxicity in human colon cancer (SW480) cells in vitro.
-
Roemerine
Roemerine is a potential active xanthine oxidase(XOD) inhibitor, XOD is a key enzyme in the pathogenesis of hyperuricemia and also a well-known target for the drug development to treat gout.